002437.SZ深圳证券交易所 · 主板 Main
Harbin Gloria Pharmaceuticals 誉衡药业
Chemical Pharmaceuticals 化学制药
¥3.45−¥0.05 · −1.43%
Open 开盘
¥3.50
High 最高
¥3.54
Low 最低
¥3.40
Prev Close 昨收
¥3.50
Volume 成交量
1.47亿股
Turnover 成交额
¥5.07亿
Mkt Cap 总市值
¥77亿
P/E 市盈率
19.2×
Recent Activity 近期动态All Filings 全部公告 →
6 significant filings since 31 May 2026: 4 on buyback, 1 on major holder selling and 1 on equity incentive. The latest, on 15 Sep 2026: 关于公司部分董事及高级管理人员减持股份的预披露公告.
自 31 May 2026 起有 6 份重大公告：buyback 4 份、major holder selling 1 份、equity incentive 1 份。最新一份（15 Sep 2026）：关于公司部分董事及高级管理人员减持股份的预披露公告。
2.505.007.5010.0012.50
Volume 成交量
7.60亿
20102014201920222026
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥77亿 | ¥63亿 | 69th highest of 158 · 158 家中第 69 高 | |
| Trailing P/E 市盈率 | 19.2x | 38.4x | 22nd lowest of 112 · 112 家中第 22 低 | |
| P/B 市净率 | 3.1x | 2.5x | 63rd highest of 157 · 157 家中第 63 高 | |
| Revenue Growth 营收增速 | -8.4% | 1.6% | 46th lowest of 156 · 156 家中第 46 低 | |
| Profit Growth 净利增速 | 18.3% | 1.9% | 61st highest of 158 · 158 家中第 61 高 | |
| Gross Margin 毛利率 | 46.4% | 50.2% | 71st lowest of 155 · 155 家中第 71 低 | |
| Net Margin 净利率 | 16.1% | 9.8% | 43rd highest of 157 · 157 家中第 43 高 | |
| Return on Equity 净资产收益率 | 7.2% | 3.1% | 25th highest of 157 · 157 家中第 25 高 | |
| Debt to Assets 资产负债率 | 23.7% | 28.0% | 64th lowest of 158 · 158 家中第 64 低 | |
| Grade Score 评级得分 | 59 | 51 | 45th highest of 157 · 157 家中第 45 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,976亿 | 92.8x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,958亿 | 38.3x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥693亿 | 73.0x | 14.1x | 54.7% | 27.5% | 18.3% | B |
| Fosun Pharma 复星医药 | ¥621亿 | 18.3x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| CSPC Innovation Pharmaceutical 石药创新 | ¥618亿 | 60.5x | 15.7x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥615亿 | 33.6x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Innocare 诺诚健华 | ¥508亿 | 55.2x | 6.6x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥477亿 | 17.8x | 5.6x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥474亿 | 13.7x | 1.9x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥333亿 | 49.5x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥309亿 | 36.4x | 4.7x | -11.4% | 10.8% | 8.1% | D |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Zelgen 泽璟制药 | ¥284亿 | 51.7x | 16.5x | 220.9% | 53.1% | 45.7% | B |
| Livzon Pharmaceutical Group 丽珠集团 | ¥269亿 | 16.1x | 2.0x | -20.3% | 22.4% | 6.6% | C |
| Harbin Gloria Pharmaceuticals 誉衡药业 | ¥77亿 | 19.2x | 3.1x | -8.4% | 16.1% | 7.2% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。